Changeflow GovPing Pharma & Drug Safety Novel Patent Compounds - Inflazome Limited (EP3...
Routine Rule Added Final

Novel Patent Compounds - Inflazome Limited (EP3759103A1)

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3759103A1 for Inflazome Limited covering novel chemical compounds (C07D derivatives) with therapeutic applications. The patent application includes inventors Miller, Van Wiltenburg, and Cooper and covers pharmaceutical compositions containing the claimed compounds.

What changed

The European Patent Office published patent application EP3759103A1 for novel C07D chemical compounds filed by Inflazome Limited. The application claims compounds classified under C07D 405/14, C07D 231/18, C07D 401/12, and C07D 405/04 with therapeutic applications indicated under A61P 29/00 and pharmaceutical formulations under A61K 31/415. The designated states cover all EU member states plus several European Economic Area countries.

For pharmaceutical and biotechnology companies, this patent publication represents potential future exclusivity for specific chemical structures targeting inflammatory conditions. Competitors developing similar pyrrazole or heterocyclic compounds should assess freedom-to-operate and consider filing observations during the opposition period.

What to do next

  1. Monitor patent register for grant or opposition proceedings
  2. Review patent claims for potential licensing opportunities
  3. Evaluate freedom-to-operate implications

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL COMPOUNDS

Publication EP3759103A1 Kind: A1 Apr 08, 2026

Applicants

Inflazome Limited

Inventors

MILLER, David, VAN WILTENBURG, Jimmy, COOPER, Matthew

IPC Classifications

C07D 405/14 20060101AFI20190907BHEP C07D 231/18 20060101ALI20190907BHEP C07D 401/12 20060101ALI20190907BHEP C07D 405/04 20060101ALI20190907BHEP A61P 29/00 20060101ALI20190907BHEP A61K 31/415 20060101ALI20190907BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
EP3759103A1
Docket
EP3759103

Who this affects

Applies to
Pharmaceutical companies Medical device makers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent examination IP licensing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!